Targeting a protein to improve immunotherapy for lung cancer
Official title: Targeting GARP-TGFbeta for Immunotherapy of Non-Small Cell Lung Cancer
Funded at Ohio State University · NIH-10882206 · Data updated 2026-11-12
This study is looking at a new treatment for non-small cell lung cancer that uses a special antibody to help your immune system fight the cancer better, and it hopes to find a way to make current therapies work more effectively for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $641,336 |
| NIH project number | 1R01CA282501-01A1 |
| Project ID | NIH-10882206 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have not responded to standard immunotherapy treatments.
✕Less likely to help
Patients with other types of lung cancer or those who have not been diagnosed with cancer may not receive any benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of immunotherapy for non-small cell lung cancer (NSCLC) by targeting a specific protein called GARP that plays a role in immune dysfunction. The study aims to develop a monoclonal antibody, PIIO-1, which selectively inhibits the activity of transforming growth factor-beta (TGFβ) in the tumor microenvironment, thereby improving the immune response against cancer cells. By using advanced mouse models, researchers will evaluate how well this approach can overcome resistance to existing cancer therapies. Patients may benefit from a more effective treatment option that could lead to better outcomes.
Why it matters
Potential benefit: If successful, this research could provide a new immunotherapy option that significantly improves treatment responses for patients with non-small cell lung cancer.
How similar studies have gone: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could lead to meaningful advancements.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Li, Zihai — Ohio State University
- Study coordinator: Li, Zihai
Related research
Other NIH-funded projects on the same topics.
-
Targeting GARP-TGFβ to Improve Immunotherapy in NSCLC
A new antibody approach aims to block a key TGFβ-related pathway in the tumor environment to help people with non-small cell lung cancer respond better to therapy.
-
Targeting DHX9 to boost viral-like immune response in Small Cell Lung Cancer
A scientist team is testing whether blocking a protein called DHX9 can make aggressive small cell lung cancer more visible to the immune system and more responsive to immunotherapy.
-
Integrated blood and radiomics to guide immunotherapy in metastatic NSCLC
A research project aims to use blood tests and advanced imaging patterns to personalize first-line immunotherapy choices for people with metastatic non-small cell lung cancer.
-
Blocking a tumor pathway to boost immunotherapy for non-small cell lung cancer
This project will see if adding a drug that blocks the Hedgehog pathway to immune checkpoint therapy helps people with non-small cell lung cancer by restoring the immune system's CD8 T cells inside tumors.
-
Improving Immunotherapy for Lung Cancer with CT Scans
This work aims to find new ways to predict which non-small cell lung cancer patients will respond best to immunotherapy using information from their routine CT scans.
-
Using CT scans and patient tests to predict who will benefit from PD‑1 immunotherapy
A computer tool combines CT scan features, blood and tumor markers, and clinical data to predict which people with advanced lung or bladder cancer are likely to benefit from PD‑1 immunotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.